Description of pharmaceutical care to assess their effectiveness on adherence to antiretroviral therapy--A randomized clinical trial

Abstract

In the framework of pharmaceutical care, pharmacotherapy follow -up requires developing, implementing and 
monitoring an individual care plan to solve drug-related problems (DRP). HIV/AIDS patients use complex regimens, 
factor that could lessen adherence, which in turn, is associated with increased viral replication and the development 
of drug-resistance. Studies have shown that perception of side-effects also lessens adherence, reinforcing the need 
to prevent, identify and solve problems during antiretroviral treatment and to avoid DRP through pharmaceutical 
care. We describe a program of pharmaceutical care for HIV/AIDS patients and our planned randomized controlled 
trial. To evaluate pharmaceutical care program for HIV-infected patients using antiretroviral treatment, through the 
Dáder method. Randomized clinical trial method was used for this study. Patients will be interviewed when they 
collected drugs or have their medical visit. Data will be collected through questionnaires demographic and self
reported adherence to the antiretrovirals and self-efficacy, for 12 months. Viral load and CD4 will be measured. The 
pharmaceutical care program will consist of color labeling the antiretrovirals and giving patients a card with 
prescription information. This study will provide information about HIV-infected patients’ pharmaceutical care and 
will hopefully provide a validated model of pharmaceutical care for specialized health centers that will supplement 
their care.